2022-09-08
OmegaTOF: Large Molecule Biotherapeutics and Protein Interactions Analysis on a Benchtop Platform
Shimadzu, together with Covalx are excited to showcase the latest development in MALDI mass spectrometry with the OmegaTOF, a benchtop MALDI TOF featuring the latest high mass detection capabilities. This presentation will highlight the ease of use and unique technology of the OmegaTOF for the rapid analysis of large molecules and protein complexes. Research and development of monoclonal antibody (mAb) products is a growing segment of the biotherapeutic market, which has only been accelerated by the recent COVID pandemic. The analysis of non-covalent complexes by mass spectrometry is stabilized using crosslinking chemistry to allow the direct analysis of protein:protein interactions (PPI). Studies of PPI such as monoclonal antibodies with their antigens of different protein sizes and stoichiometry determination will be demonstrated, including mAb binding the novel SARS-CoV2 antigen targets. Additionally, a basic epitope binning experiment will be demonstrated using two mAbs binding onto the same target measured directly at several hundred kiloDalton with no immobilization or tagging needed. Examples will also be shown for large proteins such as Keyhole Limpet Hemocyanin (KLH) and biotherapeutic monoclonal antibody products such as Immunoglobulin G (IgG) and Immunglobulin M (IgM). These demonstrate detection of several hundreds of kiloDaltons and up to the MegaDalton range with a high level of sensitivity.